NELROSFI Trademark

Trademark Overview


On Friday, December 23, 2022, a trademark application was filed for NELROSFI with the United States Patent and Trademark Office. The USPTO has given the NELROSFI trademark a serial number of 97730288. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Monday, September 30, 2024. This trademark is owned by Turning Point Therapeutics, Inc.. The NELROSFI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
nelrosfi

General Information


Serial Number97730288
Word MarkNELROSFI
Filing DateFriday, December 23, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateMonday, September 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 13, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 29, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTurning Point Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Party NameTurning Point Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events


Event DateEvent Description
Tuesday, December 27, 2022NEW APPLICATION ENTERED
Thursday, December 29, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, September 23, 2023ASSIGNED TO EXAMINER
Tuesday, September 26, 2023NON-FINAL ACTION WRITTEN
Tuesday, September 26, 2023NON-FINAL ACTION E-MAILED
Tuesday, September 26, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 14, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 14, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 8, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 15, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 9, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, January 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 13, 2024PUBLISHED FOR OPPOSITION
Tuesday, February 13, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, September 30, 2024SOU TEAS EXTENSION RECEIVED
Monday, September 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 30, 2024SOU EXTENSION 1 FILED
Monday, September 30, 2024SOU EXTENSION 1 GRANTED